TScan Therapeutics (TCRX) Operating Leases (2020 - 2026)
TScan Therapeutics (TCRX) posted quarterly Operating Leases of $52.4 million for Q1 2026, down 12.42% year-over-year from $59.9 million in Q1 2025, and down 3.66% quarter-over-quarter from $54.4 million in Q4 2025.
TScan Therapeutics (TCRX) Operating Leases (2020 - 2026) Analysis & Trends
TScan Therapeutics (TCRX) has reported Operating Leases for 7 consecutive years, with $52.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Leases fell 12.42% year-over-year to $52.4 million; the TTM figure through Mar 2026 stood at $52.4 million (down 12.42% YoY), while the FY2025 annual figure was $54.4 million, down 10.38% from the prior year.
- Operating Leases eased to $52.4 million in Q1 2026 per TCRX's latest filing, from $54.4 million in the prior quarter.
- Across five years, Operating Leases topped out at $60.7 million in Q4 2024 and bottomed at $3.0 million in Q3 2022.
- Historically, Operating Leases has averaged $46.7 million across 5 years, with a median of $54.4 million in 2025.
- Annual changes were most pronounced in 2022 — Operating Leases sank 36.74% — and 2023, when it jumped 1637.45%.
- TScan Therapeutics' Operating Leases stood at $53.0 million in 2022, then advanced by 11.56% to $59.1 million in 2023, then climbed by 2.7% to $60.7 million in 2024, then slipped by 10.38% to $54.4 million in 2025, then decreased by 3.66% to $52.4 million in 2026.
- Business Quant data shows TCRX's Operating Leases at $52.4 million in Q1 2026, $54.4 million in Q4 2025, and $56.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | TScan Therapeutics | 100.62 Mn | 100.62 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 50.40 Mn |
| Mar 31, 2026 | 52.45 Mn |
| Dec 31, 2025 | 54.44 Mn |
| Sep 30, 2025 | 56.30 Mn |
| Jun 30, 2025 | 58.12 Mn |
| Mar 31, 2025 | 59.88 Mn |
| Dec 31, 2024 | 60.74 Mn |
| Sep 30, 2024 | 55.81 Mn |
| Jun 30, 2024 | 57.01 Mn |
| Mar 31, 2024 | 58.18 Mn |
| Dec 31, 2023 | 59.14 Mn |
| Sep 30, 2023 | 52.66 Mn |
| Jun 30, 2023 | 53.81 Mn |
| Mar 31, 2023 | 51.97 Mn |
| Dec 31, 2022 | 53.01 Mn |
| Sep 30, 2022 | 3.03 Mn |
| Jun 30, 2022 | 3.50 Mn |
| Mar 31, 2022 | 3.95 Mn |
| Dec 31, 2021 | 4.39 Mn |
| Sep 30, 2021 | 4.79 Mn |